Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 billion. Investors are closely watching upcoming drug trial results later this year, which are crucial for supporting Novartis' premium valuation, reflected in its P/E ratio of 21.30. Financial health metrics like a Debt-to-Equity ratio of 1.22 and a Current Ratio of 0.85 provide insight into the company's stability ahead of the earnings release on July 21, 2026.
ResearchAndMarkets.com released a comprehensive report analyzing over 1,230 bioinformatics collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, including upfront payments, milestones, royaltie...
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
